PD-009Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC. (2nd July 2019) - Kaseb, A; Vence, L; Blando, J; Yadav, S; Ikoma, N; Pestana, R; Vauthey, J; Cao, H; Chun, Y; Sakamura, D; Wolff, R; Yao, J; et al.